B. Amendment to the Specification:

1. Please revise the paragraph of the application appearing under the section entitled "Cross reference to Related Applications" on page 2, beginning at line 4, as follows:

The present application is a continuation of U.S. Application No. 10/215,492, filed August 8, 2002, now U.S. Patent No. 6,709,664, which is a continuation of U.S. Application No. 09/663,218, filed September 15, 2000, now U.S. Patent No. 6,461,619, which ~~The present application~~ claims priority to international patent application number PCT/US99/04588, filed March 3, 1999, which claims priority to provisional patent application serial number 60/078,043, filed March 16, 1998.

2. Please revise the paragraph beginning on page 6, line 23, as follows:

As noted above, topical administration and topical dosage forms are generally preferred for the present methods. However, any of the numerous dosage forms described in the literature for the administration for selegiline may be used and may include desmethylselegiline as desired. For example, U.S. 4,812,481 discloses the use of selegiline, in combination with amantadine, in oral, pectoral, internal, pulmonary, rectal, nasal, vaginal, lingual, intravenous, intraarterial, intracardial, intramuscular, intraperitoneal, intracutaneous, and subcutaneous formulations. ~~U.S. 4,192,550 describes a d~~Dosage forms for selegiline having an outer wall with one or more pores in the wall impermeable to selegiline but permeable to external fluids have been described. This dosage form may have applicability for oral, sublingual, or buccal administration. Similarly, ~~U.S. 4,387,615 discloses~~ a variety of selegiline compositions, including tablets, pills, capsules, powders, aerosols, suppositories, skin patches, parenterals, and oral liquids, including oil suspensions, solutions and emulsions have been described. Further disclosed ~~therein~~ are selegiline-containing sustained release (long acting) formulations and devices.

3. Please revise the paragraph beginning on page 7, line 15, as follows:

Transdermal dosage forms can be prepared utilizing a variety of techniques that have been described in the art. Examples may be found in U.S. patent numbers 4,861,800; 4,868,218; 5,128,145; 5,190,763; and 5,242,950; and in foreign patent documents EP-A 404807; EP-A

509761; and EP-A 593807. A monolithic patch structure can be utilized in which drug is directly incorporated into the adhesive and this mixture is cast onto a backing sheet. EP-A 593807 describes a composition in which selegiline is administered as an acid addition salt by incorporating it into a multi layer patch which promotes a conversion of the salt into the free base form of selegiline. One can also employ a device using a lyotropic liquid crystalline composition in which, for example, 5-15% of selegiline is combined with a mixture of liquid and solid polyethylene glycols, a polymer and a non-ionic surfactant, optionally with the addition of propylene glycol and an emulsifying agent. ~~For f~~Further details on the preparation of such transdermal formulations~~, reference can be made to EP-A-5509761~~ are found in the patent literature.

4. Please revise the paragraph beginning on page 7, line 27, as follows:

Buccal and sublingual dosage forms of selegiline and/or desmethylselegiline may be prepared utilizing techniques described in, for example, U.S. 5,192,550; 5,221,536; 5,266,332; 5,057,321; 5,446,070; ~~4,826,379;~~ or 5,354,885.